Dr. Mark A. Jacobs, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 196
Licensed in Texas since 1977, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Baylor College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
TX license E8588 (first issued 1977; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Medicare patients and services
- Medicare patients, 2024
- 196
- Services billed
- 287
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 89 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 102 | 102 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Houston, TX | 224 |
| Premarin (estrogens, conjugated) Other prescribers in Houston, TX | 80 |
| Raloxifene Hcl Other prescribers in Houston, TX | 66 |
| Prempro (estrogen,con/m-progest acet) | 39 |
| Alendronate Sodium Other prescribers in Houston, TX | 37 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Houston, TX | 37 |
| Estradiol (Twice Weekly) (estradiol) Other prescribers in Houston, TX | 28 |
| Fluconazole Other prescribers in Houston, TX | 24 |
| Progesterone (progesterone, micronized) Other prescribers in Houston, TX | 23 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Houston, TX | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $62.17 in total to this clinician.
| Exact Sciences Corporation | $40.30 |
|---|---|
| Astellas Pharma Global Development | $21.87 |
| Food and Beverage | $62.17 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $345,578 in research payments for these studies, mostly to the institutions running them.
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms
Astellas Pharma Global Development - Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Exeltis, USA Inc. · Completed · NCT05461573 - Study name not reported
Organon Llc - LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Exeltis, USA Inc. · Active, not recruiting · NCT05303636 - A phase 3B, open-label, single-arm study in adolescent and adult femal
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.